Effectiveness of Nifedipine in Threatened Preterm Labor: a Randomized Trial
Overview
Affiliations
Objective: Threatened preterm labor is a condition in which regular uterine contractions occur at least 1 time in 10 minutes and persist for more than 30 minutes before completion of 37 weeks of gestation without dilatation of the cervix. In preterm labor with cervical dilatation, the efficacy of tocolytics was proven for prolonging pregnancy. However, in threatened preterm labor, the efficacy of tocolytics has not yet been well studied. This study aimed to evaluate the effectiveness of nifedipine versus a placebo for inhibiting uterine contraction in threatened preterm labor.
Materials And Methods: A randomized, double-blinded, placebo-controlled study with 206 threatened preterm labor patients was undertaken. The participants were randomly allocated into either nifedipine or placebo groups. The proportion of patients with successful treatment, gestational age at delivery, and neonatal outcome were compared between the 2 groups.
Results: After 90 minutes of treatment, 88.3% of the nifedipine group and 69.9% of the placebo group had no uterine contraction (<0.001). Nifedipine led to successful treatment outcomes in 77.6% of the total participants compared with 49.5% in the placebo group (<0.001). The remainder of the participants from both groups needed a second-line tocolytic drug. Of these, 9.7% in the nifedipine group delivered within 48 hours compared with 12.6% in the placebo group (>0.05). Mean gestation age at delivery and neonatal complications for both groups were not significantly different.
Conclusion: Nifedipine had a higher success rate for inhibiting threatened preterm contractions.
Long-acting nifedipine in the management of essential hypertension: a review for cardiologists.
Hazra P, Mehta A, Desai B, Pandey U, Mehta K, Bajpai S Am J Cardiovasc Dis. 2025; 14(6):396-413.
PMID: 39839565 PMC: 11744219. DOI: 10.62347/RPMZ6407.
Off-label use of medicines in South Africa: a review.
Ngcobo N, Mathibe L Orphanet J Rare Dis. 2024; 19(1):448.
PMID: 39614329 PMC: 11607944. DOI: 10.1186/s13023-024-03476-4.
Hassan A, Waseem H, Aldardeir N, Nasief H, Khadawardi K, Alwazzan A Cureus. 2023; 15(7):e42422.
PMID: 37637555 PMC: 10448571. DOI: 10.7759/cureus.42422.
β3 Receptor Signaling in Pregnant Human Myometrium Suggests a Role for β3 Agonists as Tocolytics.
Buxton I, Asif H, Barnett S Biomolecules. 2023; 13(6).
PMID: 37371585 PMC: 10296559. DOI: 10.3390/biom13061005.
Assessment of the tocolytic nifedipine in preclinical primary models of preterm birth.
Arman B, Binder N, de Alwis N, Beard S, Debruin D, Hayes A Sci Rep. 2023; 13(1):5646.
PMID: 37024530 PMC: 10079980. DOI: 10.1038/s41598-023-31077-x.